141 related articles for article (PubMed ID: 20881555)
21. Reversal of Vasospasm with Clazosentan After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study.
Higashida RT; Bruder N; Gupta R; Guzman R; Hmissi A; Marr A; Mayer SA; Roux S; Weidauer S; Aldrich EF
World Neurosurg; 2019 Aug; 128():e639-e648. PubMed ID: 31054336
[TBL] [Abstract][Full Text] [Related]
22. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).
Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Bach D; Frey A; Marr A; Roux S; Kassell N
Lancet Neurol; 2011 Jul; 10(7):618-25. PubMed ID: 21640651
[TBL] [Abstract][Full Text] [Related]
23. Clinical utility of multislice computed tomographic angiography for detection of cerebral vasospasm in acute subarachnoid hemorrhage.
Joo SP; Kim TS; Kim YS; Moon KS; Lee JK; Kim JH; Kim SH
Minim Invasive Neurosurg; 2006 Oct; 49(5):286-90. PubMed ID: 17163342
[TBL] [Abstract][Full Text] [Related]
24. Clazosentan for patients with subarachnoid haemorrhage: lessons learned.
Wong GK; Poon WS
Lancet Neurol; 2011 Oct; 10(10):871; author reply 871-2. PubMed ID: 21939894
[No Abstract] [Full Text] [Related]
25. Patient phenotypes associated with outcomes after aneurysmal subarachnoid hemorrhage: a principal component analysis.
Ibrahim GM; Morgan BR; Macdonald RL
Stroke; 2014 Mar; 45(3):670-6. PubMed ID: 24425125
[TBL] [Abstract][Full Text] [Related]
26. Clazosentan (Actelion).
Uhlmann D
Curr Opin Investig Drugs; 2006 Mar; 7(3):272-81. PubMed ID: 16555688
[TBL] [Abstract][Full Text] [Related]
27. Predictors analysis of symptomatic cerebral vasospasm after subarachnoid hemorrhage.
Yin L; Ma CY; Li ZK; Wang DD; Bai CM
Acta Neurochir Suppl; 2011; 110(Pt 2):175-8. PubMed ID: 21125467
[TBL] [Abstract][Full Text] [Related]
28. Dissociation of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan.
Sabri M; Ai J; Macdonald RL
Stroke; 2011 May; 42(5):1454-60. PubMed ID: 21454820
[TBL] [Abstract][Full Text] [Related]
29. Endothelin receptor antagonists for subarachnoid hemorrhage.
Guo J; Shi Z; Yang K; Tian JH; Jiang L
Cochrane Database Syst Rev; 2012 Sep; (9):CD008354. PubMed ID: 22972119
[TBL] [Abstract][Full Text] [Related]
30. Effect of clazosentan in patients with aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials.
Wang X; Li YM; Li WQ; Huang CG; Lu YC; Hou LJ
PLoS One; 2012; 7(10):e47778. PubMed ID: 23082215
[TBL] [Abstract][Full Text] [Related]
31. Vasospasm.
Dumont AS; Kassell NF
J Neurosurg; 2005 Jul; 103(1):1-3; discussion 3. PubMed ID: 16121964
[No Abstract] [Full Text] [Related]
32. Letter: Clinical Benefit of Clazosentan in Vasospasm After Subarachnoid Hemorrhage: Are We There Yet?
Katiyar V; Kale A; Sharma R; Ganeshkumar A; Borkar SA
Neurosurgery; 2023 Feb; 92(2):e37-e40. PubMed ID: 36637286
[No Abstract] [Full Text] [Related]
33. Global cerebral atrophy after subarachnoid hemorrhage: a possible marker of acute brain injury and assessment of its impact on outcome.
Tam AK; Ilodigwe D; Li Z; Schweizer TA; Macdonald RL
Acta Neurochir Suppl; 2013; 115():17-21. PubMed ID: 22890637
[TBL] [Abstract][Full Text] [Related]
34. Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update.
Vergouwen MD; Algra A; Rinkel GJ
Stroke; 2012 Oct; 43(10):2671-6. PubMed ID: 22871682
[TBL] [Abstract][Full Text] [Related]
35. Clazosentan: an endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage.
Macdonald RL
Expert Opin Investig Drugs; 2008 Nov; 17(11):1761-7. PubMed ID: 18922111
[TBL] [Abstract][Full Text] [Related]
36. Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials.
Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Frey A; Marr A; Roux S; Kassell NF
Neurocrit Care; 2010 Dec; 13(3):416-24. PubMed ID: 20838933
[TBL] [Abstract][Full Text] [Related]
37. Impact of global cerebral atrophy on clinical outcome after subarachnoid hemorrhage.
Tam AK; Kapadia A; Ilodigwe D; Li Z; Schweizer TA; Macdonald RL
J Neurosurg; 2013 Jul; 119(1):198-206. PubMed ID: 23662822
[TBL] [Abstract][Full Text] [Related]
38. Vasospasm after aneurysmal subarachnoid hemorrhage: need for further study.
Pearl JD; Macdonald RL
Acta Neurochir Suppl; 2008; 105():207-10. PubMed ID: 19066110
[TBL] [Abstract][Full Text] [Related]
39. Effect of endothelin-receptor antagonists on delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage remains unclear.
Vergouwen MD
Stroke; 2009 Dec; 40(12):e714; author reply e715-6. PubMed ID: 19875735
[No Abstract] [Full Text] [Related]
40. Clazosentan for Aneurysmal Subarachnoid Hemorrhage: An Updated Meta-Analysis with Trial Sequential Analysis.
Cho SS; Kim SE; Kim HC; Kim WJ; Jeon JP
World Neurosurg; 2019 Mar; 123():418-424.e3. PubMed ID: 30508597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
